|
Calderon C, Gomez D, Carmona-Bayonas A, Hernandez R, Ghanem I, Gil Raga M, Ostios Garcia L, Garcia Carrasco M, Lopez de Ceballos MH, Ferreira E, Jimenez-Fonseca P. Social support, coping strategies and sociodemographic factors in women with breast cancer. Clin Transl Oncol. 2021 Sep;23(9):1955-1960. doi: 10.1007/s12094-021-02592-y. Epub 2021 Apr 10. PubMed PMID: 33840046.
AÑO: 2021; IF: 3.34
|
33840046
|
Jimenez-Fonseca P, Carmona-Bayonas A, Martinez-Torron A, Alsina M, Custodio A, Serra O, Cacho Lavin D, Limon ML, Sauri T, Lopez F, Visa L, Granja M, Martinez Lago N, Arrazubi V, Vidal Tocino R, Hernandez R, Aguado G, Cano JM, Martin Carnicero A, Mangas M, Pimentel P, Fernandez Montes A, Macias Declara I, Longo F, Ramchandani A, Martin Richard M, Hurtado A, Azkarate A, Hernandez Perez C, Serrano R, Gallego J; AGAMENON-SEOM study group. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Ther Adv Med Oncol. 2021 Jun 17;13:17588359211019672. doi: 10.1177/17588359211019672. eCollection 2021. PubMed PMID: 34211587; PubMed Central PMCID: PMC8216357.
AÑO: 2021; IF: 5.485
|
|
Fernandez Montes A, Carmona-Bayonas A, Jimenez-Fonseca P, Vazquez Rivera F, Martinez Lago N, Covela Rua M, Cousillas Castineiras A, Gonzalez Villarroel P, De la Camara Gomez J, Mendez JCM, Carriles Fernandez C, Sanchez Canovas M, Garcia Garcia T. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. Sci Rep. 2021 Jul 12;11(1):14321. doi: 10.1038/s41598-021-93732-5. PubMed PMID: 34253805; PubMed Central PMCID: PMC8275736.
AÑO: 2021; IF: 4.996
|
|
Castanon E, Sanchez-Arraez A, Alvarez-Mancenido F, Jimenez-Fonseca P, Carmona-Bayonas A. Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings. Eur J Cancer. 2020 Sep;136:159-168. doi: 10.1016/j.ejca.2020.06.003. Epub 2020 Jul 19. Erratum In: Eur J Cancer. 2020 Nov 5;: PubMed PMID: 32698098.
AÑO: 2020; IF: 9.162
|
|
Viudez A, Carmona-Bayonas A, Gallego J, Lacalle A, Hernandez R, Cano JM, Macias I, Custodio A, Martinez de Castro E, Sanchez A, Iglesia L, Reguera P, Visa L, Azkarate A, Sanchez-Canovas M, Mangas M, Limon ML, Martinez-Torron A, Asensio E, Ramchandani A, Martin-Carnicero A, Hurtado A, Cerda P, Garrido M, Sanchez-Bayonas R, Serrano R, Jimenez-Fonseca P; AGAMENON Study Group. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. Clin Transl Oncol. 2020 May;22(5):734-750. doi: 10.1007/s12094-019-02183-y. Epub 2019 Aug 5. PubMed PMID: 31385226.
AÑO: 2020; IF: 3.405
|